On September 3, 2024, Kristen Oelschlager, Chief Operating Officer of Castle Biosciences Inc (CSTL, Financial), sold 5,832 shares of the company. The transaction was documented in a recent SEC Filing. Following this sale, the insider now owns 134,841 shares of Castle Biosciences Inc.
Castle Biosciences Inc specializes in providing diagnostic tests that offer valuable insights for treatment decisions across various cancer types, enhancing the understanding and management of the disease.
Over the past year, Kristen Oelschlager has sold a total of 24,407 shares and has not made any purchases of the company's stock. This recent transaction is part of a broader trend observed within the company, where there have been 44 insider sells and no insider buys over the past year.
Shares of Castle Biosciences Inc were trading at $29.21 on the day of the transaction. The company currently holds a market cap of $817.68 million.
According to the GF Value, the intrinsic value of the stock is estimated at $48.15, suggesting that Castle Biosciences Inc is significantly undervalued with a price-to-GF-Value ratio of 0.61. The GF Value is calculated based on historical trading multiples, a GuruFocus adjustment factor, and future business performance estimates.
This valuation insight, combined with the insider selling trend, provides investors with critical data points for evaluating their investment decisions in Castle Biosciences Inc.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
